Home > Publications Database > Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease. > print

001     154382
005     20240320115506.0
024 7 _ |a 10.1002/mds.28192
|2 doi
024 7 _ |a pmid:33179332
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:88324526
|2 altmetric
037 _ _ |a DZNE-2021-00235
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Markaki, Ioanna
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
260 _ _ |a New York, NY
|c 2020
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1617289421_15300
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1531-8257 not unique: **3 hits**.
520 _ _ |a Cognitive impairment is common in patients with PD. Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease-specific signature to predict PD dementia exists to date.The aim of this study was to investigate CSF markers associated with cognition in early PD.A high-throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project. Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini-Mental State Examination.Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90). Of 14 proteins in CSF that differed in levels between groups, increased kininogen-1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders.Kininogen-1 levels in CSF may serve as a marker of cognitive impairment in PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a kininogen-1
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 2 |a Cognition Disorders: diagnosis
|2 MeSH
650 _ 2 |a Cognition Disorders: etiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Kininogens
|2 MeSH
650 _ 2 |a Mental Status and Dementia Tests
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
700 1 _ |a Bergström, Sofia
|b 1
700 1 _ |a Tsitsi, Panagiota
|b 2
700 1 _ |a Remnestål, Julia
|b 3
700 1 _ |a Månberg, Anna
|b 4
700 1 _ |a Hertz, Ellen
|b 5
700 1 _ |a Paslawski, Wojciech
|b 6
700 1 _ |a Sorjonen, Kimmo
|b 7
700 1 _ |a Uhlén, Mathias
|b 8
700 1 _ |a Mangone, Graziella
|b 9
700 1 _ |a Carvalho, Stephanie
|b 10
700 1 _ |a Rascol, Olivier
|b 11
700 1 _ |a Meissner, Wassilios G
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Magnin, Eloi
|b 13
700 1 _ |a Wüllner, Ullrich
|0 P:(DE-2719)2000056
|b 14
|u dzne
700 1 _ |a Corvol, Jean-Christophe
|b 15
700 1 _ |a Nilsson, Peter
|b 16
700 1 _ |a Svenningsson, Per
|b 17
773 _ _ |a 10.1002/mds.28192
|g Vol. 35, no. 11, p. 2101 - 2106
|0 PERI:(DE-600)2041249-6
|n 11
|p 2101 - 2106
|t Movement disorders
|v 35
|y 2020
|x 1531-8257
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154382/files/mds.28192.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154382/files/mds.28192.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154382
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2000056
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner ; AG Wüllner 2
|l Biomarkers for Parkinson's disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011302
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21